Neurocrine Biosciences Reports Year-End 2016 Results and Provides Investor Update for 2017
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on semiconductor selloff as AI spending concerns mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Needham Starts NeoVolta (NEOV) at Buy
Neurocrine Bio. (NBIX) PT Raised to $100 at H.C. Wainwright on Positive Survey Data
February 16, 2017 7:47 AM ESTHC Wainwright and Co. analyst Andrew Fein reiterates Buy rating and raises price target on Neurocrine Biosciences (NASDAQ: NBIX) to $100 (from $80), suggesting the company's shares are undervalued by nearly 60%, as proprietary physician surveys help identify the proper value post Opicapone deal.
Fein writes, "Correcting the value proposition surrounding opicapone. In our view, last week's... More
Needham & Company Reiterates Buy Rating and $62 PT on Neurocrine Biosciences (NBIX) Ahead of 2017 Catalyst
February 15, 2017 7:58 AM ESTNeedham & Company analyst Alan Carr reiterates Buy and $62 price target on Neurocrine Biosciences (NASDAQ: NBIX), as the company remains focused on upcoming Ingrezza launch and Phase 2 pediatric Tourette Syndrome data due May 2017.
Carr comments, "Company continues to prepare for Ingrezza launch ahead of... More
Baird Reiterates Outperform Rating and $66 PT on Neurocrine Biosciences (NBIX) Following 4Q Results
February 15, 2017 5:56 AM ESTBaird analyst Brian Skorney reiterates Outperform rating and $66 price target on Neurocrine Biosciences (NASDAQ: NBIX), noting the company reported in-line results ahead of Ingrezza launch.
Skorney comments, "No change to outlook heading into Ingrezza approval. Neurocrine reported a solid end to the year, modestly... More
